EurekAlert!: Carlos Collet, MD, Ph.D., joins CRF® as director, cardiovascular imaging, physiology and translational therapeutics
Carlos Collet, MD, Ph.D., joins CRF® as director, cardiovascular imaging, physiology and translational therapeutics
Nasdaq: COEPTIS, Inc. Establishes GEAR Therapeutics to Advance Innovative Cancer Cell Therapy into First-in-Human Studies
COEPTIS, Inc. has established GEAR Therapeutics as a majority-owned subsidiary to advance its GEAR-modified natural killer (NK) cell therapy into first-in-human studies targeting various cancers and ...
COEPTIS, Inc. Establishes GEAR Therapeutics to Advance Innovative Cancer Cell Therapy into First-in-Human Studies
Nasdaq: Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to ...
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to ...
Seeking Alpha: Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer
Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer
Business Insider: Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the Discovery of Cancer Therapy by Inhibition of Negative Immune ...
Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the Discovery of Cancer Therapy by Inhibition of Negative Immune ...
therapeutics, treatment and care of a patient for the purpose of both preventing and combating disease or alleviating pain or injury. The term comes from the Greek therapeutikos, which means “inclined to serve.”